GlassScriptPhysician profile
Manish J Dave
NPI 1194011478
$32,725.97
in general payments reported to CMS, 2019-2025
25 companies · $918 in 2025
The $918 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.25 · 2022: $2,109 · 2023: $27K · 2024: $2,792 · 2025: $918.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $26K · Consulting Fee: $2,140 · Food and Beverage: $1,769 · Travel and Lodging: $180 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $26,474.00 |
| Consulting Fee | $2,140.00 |
| Food and Beverage | $1,768.78 |
| Travel and Lodging | $180.11 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $31,204.23 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $289.11 | 2022-2025 | Opdivo, Krazati, Opdualag |
| Astrazeneca Pharmaceuticals LP | $165.68 | 2025 | Enhertu, Tagrisso |
| Novartis Pharmaceuticals Corporation | $107.49 | 2024-2025 | |
| Celgene Corporation | $102.31 | 2022-2025 | Reblozyl |
| Incyte Corporation | $100.34 | 2024-2025 | Jakafi |
| Abbvie INC. | $89.94 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.46 | 2024-2025 | |
| Janssen Biotech, INC. | $77.55 | 2024-2025 | Darzalex, Talvey, Tecvayli |
| Regeneron Healthcare Solutions, INC. | $69.61 | 2025 | Libtayo, Lynozyfic |
| Gilead Sciences, INC. | $66.40 | 2024-2025 | Trodelvy |
| Daiichi Sankyo INC. | $60.55 | 2025 | Datroway, Injectafer |
| Foundation Medicine, INC. | $39.63 | 2023 | |
| Agios Pharmaceuticals, INC. | $39.52 | 2024-2025 | Pyrukynd |
| Blue Earth Diagnostics | $32.74 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.01 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $25.24 | 2024 | Ninlaro |
| Myriad Genetic Laboratories, INC. | $22.29 | 2023 | Precisetumor |
| Pharmacosmos Therapeutics INC. | $19.43 | 2024 | Monoferric |
| Glaxosmithkline, LLC. | $19.07 | 2025 | Blenrep, Ojjaara |
| Eisai INC. | $19.07 | 2025 | |
| Pfizer INC. | $19.00 | 2024 | |
| Exelixis INC. | $18.12 | 2024 | Cabometyx |
| Solventum Corporation | $15.93 | 2025 | Prevena, V.A.C.Instill, V.A.C.Ulta |
| Lilly USA, LLC | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Dave listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.